Literature DB >> 22167224

Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis.

Fredrik Romi1, Shigeaki Suzuki, Norihiro Suzuki, Axel Petzold, Gordon T Plant, Nils Erik Gilhus.   

Abstract

Myasthenia gravis (MG) is an autoimmune disease characterized by skeletal muscle weakness mainly caused by acetylcholine receptor antibodies. MG can be divided into generalized and ocular, and into early-onset (<50 years of age) and late-onset (≥50 years of age). Anti-Kv1.4 antibodies targeting α-subunits (Kv1.4) of the voltage-gated potassium K(+) channel occurs frequently among patients with severe MG, accounting for 18% of a Japanese MG population. The aim of this study was to characterize the clinical features and serological associations of anti-Kv1.4 antibodies in a Caucasian MG population with mild and localized MG. Serum samples from 129 Caucasian MG patients with mainly ocular symptoms were tested for the presence of anti-Kv1.4 antibodies and compared to clinical and serological parameters. There were 22 (17%) anti-Kv1.4 antibody-positive patients, most of them women with late-onset MG, and all of them with mild MG. This contrasts to the Japanese anti-Kv1.4 antibody-positive patients who suffered from severe MG with bulbar symptoms, myasthenic crisis, thymoma, myocarditis and prolonged QT time on electrocardiography, despite equal anti-Kv1.4 antibody occurrence in both populations. No other clinical or serological parameters influenced anti-Kv1.4 antibody occurrence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22167224     DOI: 10.1007/s00415-011-6344-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

Review 1.  The voltage-gated potassium channels and their relatives.

Authors:  Gary Yellen
Journal:  Nature       Date:  2002-09-05       Impact factor: 49.962

2.  Clinical and immunological differences between early and late-onset myasthenia gravis in Japan.

Authors:  Shigeaki Suzuki; Kimiaki Utsugisawa; Yuriko Nagane; Takashi Satoh; Masataka Kuwana; Norihiro Suzuki
Journal:  J Neuroimmunol       Date:  2010-11-12       Impact factor: 3.478

3.  Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis.

Authors:  Shigeaki Suzuki; Takashi Satoh; Hidekata Yasuoka; Yasuhito Hamaguchi; Kortaro Tanaka; Yutaka Kawakami; Norihiro Suzuki; Masataka Kuwana
Journal:  J Neuroimmunol       Date:  2005-09-22       Impact factor: 3.478

4.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

5.  Matrix metalloproteinases in myasthenia gravis.

Authors:  Geir Helgeland; Axel Petzold; Steven Paul Luckman; Nils Erik Gilhus; Gordon T Plant; Fredrik Robert Romi
Journal:  Eur Neurol       Date:  2011-01-06       Impact factor: 1.710

6.  Anti-Heat Shock Protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barré syndrome.

Authors:  Geir Helgeland; Axel Petzold; Jana Midelfart Hoff; Nils Erik Gilhus; Gordon T Plant; Fredrik Robert Romi
Journal:  J Neuroimmunol       Date:  2010-08-25       Impact factor: 3.478

7.  Clinical spectrum of voltage-gated potassium channel autoimmunity.

Authors:  K M Tan; V A Lennon; C J Klein; B F Boeve; S J Pittock
Journal:  Neurology       Date:  2008-05-13       Impact factor: 9.910

Review 8.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

9.  Agrin-induced phosphorylation of the acetylcholine receptor regulates cytoskeletal anchoring and clustering.

Authors:  L S Borges; M Ferns
Journal:  J Cell Biol       Date:  2001-04-02       Impact factor: 10.539

10.  Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.

Authors:  John McConville; Maria Elena Farrugia; David Beeson; Uday Kishore; Richard Metcalfe; John Newsom-Davis; Angela Vincent
Journal:  Ann Neurol       Date:  2004-04       Impact factor: 10.422

View more
  14 in total

Review 1.  Neuro-ophthalmology update.

Authors:  Konrad P Weber; Dominik Straumann
Journal:  J Neurol       Date:  2013-09-26       Impact factor: 4.849

Review 2.  Myasthenia gravis - autoantibody characteristics and their implications for therapy.

Authors:  Nils Erik Gilhus; Geir Olve Skeie; Fredrik Romi; Konstantinos Lazaridis; Paraskevi Zisimopoulou; Socrates Tzartos
Journal:  Nat Rev Neurol       Date:  2016-04-22       Impact factor: 42.937

Review 3.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 4.  Myasthenia gravis: an update for the clinician.

Authors:  J P Sieb
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 5.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

Review 6.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Alexandra M Haugh; John C Probasco; Douglas B Johnson
Journal:  Expert Opin Drug Saf       Date:  2020-03-11       Impact factor: 4.250

Review 7.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

Review 8.  Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

Review 9.  Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.

Authors:  Miriam L Fichtner; Ruoyi Jiang; Aoibh Bourke; Richard J Nowak; Kevin C O'Connor
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

10.  B Cell Immunophenotyping and Transcriptional Profiles of Memory B Cells in Patients with Myasthenia Gravis.

Authors:  Young Gi Min; Canaria Park; Young-Nam Kwon; Je-Young Shin; Jung-Joon Sung; Yoon-Ho Hong
Journal:  Exp Neurobiol       Date:  2019-12-31       Impact factor: 3.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.